TP53 and Li-Fraumeni syndrome: Tumor cells harboring wildtype TP53 are more likely to senesce in response to genotoxic therapies [33, 34], whereas cells carrying mutant TP53 (Li-Fraumeni syndrome) overcome senescence readily and are prone to develop cancer [35].